Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) announced on Wednesday that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel, investigational KRAS G12D-targeted protein degrader, versus docetaxel in people with KRAS G12D-mutated locally advanced (unresectable) or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or after initial platinum-based chemotherapy and checkpoint inhibitor therapy (CPI).
Setidegrasib is an investigational targeted protein degrader designed to degrade and eliminate the disease-driving KRAS G12D protein. By removing this protein, setidegrasib may help disrupt cancer cell signalling and destroy cancer cells. This Phase 3 study in previously treated NSCLC builds on early clinical evidence published in The New England Journal of Medicine in March 2026, which demonstrated anti-tumor activity and a manageable safety profile in patients with KRAS G12D-mutated solid tumours, supporting the proposed mechanism of action of setidegrasib.
A Phase 3 study of setidegrasib in front-line pancreatic ductal adenocarcinoma (PDAC) was launched in April 2026.
Astellas plans to present translational analyses from the Phase 1 study of setidegrasib in patients with KRAS G12D-mutated PDAC at the upcoming AACR Conference on Pancreatic Cancer, providing further insight into mechanisms of response, resistance and potential rational combination approaches in pancreatic cancer.
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
Sichuan Kelun-Biotech announces Phase III OptiTROP-Lung04 study results at 2026 ESMO
Bio-Thera reports promising BAT8008 - BAT1308 combination lung cancer clinical data at ESMO 2026
Zai Lab reports promising Phase 1b results for zocilurtatug pelitecan in small cell lung cancer
IHI and Bristol Myers Squibb launch initiative to expand cancer clinical trial access
Oracle partners AstraZeneca for AI-enabled healthcare innovation
GSK reports 61% response rate for investigational lung cancer drug
Omeros receives negative EU opinion on narsoplimab after re-examination
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer
Sophos IRB and ALCMI partner to support lung cancer research
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK